Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples